Key result
Higher in-treatment diastolic blood pressure variability independently predicted the composite of cardiovascular death, MI, or stroke.
Why the study?
Does high in-treatment visit-to-visit blood pressure variability predict cardiovascular events in hypertensive patients with left ventricular hypertrophy?
RCT (n=8,505)
randomized
Does high in-treatment visit-to-visit blood pressure variability predict cardiovascular events in hypertensive patients with left ventricular hypertrophy?
Higher in-treatment visit-to-visit blood pressure variability independently predicts cardiovascular events and stroke in hypertensive patients with left ventricular hypertrophy.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in LVH; leaves open variability as a modifiable target.
BACKGROUND: Assessment of antihypertensive treatment is normally based on the mean value of a number of blood pressure (BP) measurements. However, it is uncertain whether high in-treatment visit-to-visit BP variability may be harmful in hypertensive patients with left ventricular hypertrophy (LVH). METHODS: In 8505 patients randomized to losartan vs. atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events). RESULTS: In multiple regression models adjusted for mean BP6-24 months and treatment allocation, neither high BP6-24 months SD nor wide range were related to TOD at 24 months, except for a weak association between Sokolow-Lyon voltage and DBP6-24 months SD and range (both β = 0.04, P < 0.01). Independently of mean BP6-24 months, treatment allocation, TOD and baseline characteristics in Cox regression models, CEP after 24 months was associated with DBP6-24 months SD [hazard ratio per 1 mmHg increase1.04, 95% confidence interval (95% CI) 1.01-1.06, P = 0.005], range (hazard ratio 1.02, 95% CI 1.01-1.03, P = 0.004), SBP6-24 months SD (hazard ratio 1.01, 95% CI 0.99-1.02, P = 0.07) and range (hazard ratio 1.006, 95% CI 1.001-1.01, P = 0.04). Adjusted for the same factors, stroke was associated with DBP6-24 months SD (hazard ratio 1.06, 95% CI 1.02-1.10, P = 0.001), range (hazard ratio 1.03, 95% CI 1.01-1.04, P = 0.001), SBP6-24 months SD (hazard ratio 1.02, 95% CI 1.002-1.04, P = 0.04) and range (hazard ratio 1.008, 95% CI 1.001-1.02, P = 0.05), but MI was not. CONCLUSION: In LIFE patients, higher in-treatment BP6-24 months variability was independently of mean BP6-24 months associated with later CEP and stroke, but not with MI or TOD after 24 months.
No takes yet. Share an insight, caveat, or question.
Vishram et al. (2015) conducted an RCT in Hypertension with left ventricular hypertrophy (n=8,505). Blood pressure variability was evaluated on Composite endpoint of cardiovascular death, nonfatal myocardial infarction or stroke occurring after 24 months (HR 1.04, 95% CI 1.01-1.06, p=0.005). Higher in-treatment diastolic blood pressure variability independently predicted the composite of cardiovascular death, MI, or stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: